Roche Holding AG Ordinary Shares new RHHVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
-
Roche Halts Development of Obesity Drug Candidate
-
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
-
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial — Update
-
European Pharma Leaders Push for National Reforms to Boost Investment
-
Roche's Susvimo Gets European Union Approval
-
Hutchmed Enters Licensing Agreement With GSK for Cancer Drug
-
Roche, Simcere Pharma Strike Drug Licensing Deal
Trading Information
- Previous Close Price
- $442.60
- Day Range
- $415.07–442.60
- 52-Week Range
- $318.81–490.33
- Bid/Ask
- $401.00 / $460.00
- Shares Outstanding
- 796.77M
- Market Cap
- $340.70B
- Volume/Avg
- 74 / 5,563
Key Statistics
- Price/Earnings (Normalized)
- 19.57
- Price/Sales
- 4.49
- Dividend Yield (Trailing)
- 2.90%
- Dividend Yield (Forward)
- 2.90%
- Dividend Payment Schedule
- Mar
- Total Yield
- 2.90%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 112,774
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RHHVF
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.57 | 44.80 | 23.91 |
Price/Book Value | 8.71 | 8.47 | — |
Price/Sales | 4.49 | 5.36 | 7.16 |
Price/Cash Flow | 14.06 | 16.10 | 19.73 |
Price/Earnings
RHHVF
MRK
ABBV
Financial Strength
|
Metric
|
RHHVF
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.80 | 0.71 | 0.49 |
Current Ratio | 1.23 | 1.32 | 0.81 |
Interest Coverage | 13.49 | 4.28 | 3.89 |
Quick Ratio
RHHVF
MRK
ABBV
Profitability
|
Metric
|
RHHVF
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | 6.27% | 14.29% |
Return on Equity (Normalized) | 48.77% | 16.68% | — |
Return on Invested Capital (Normalized) | 23.90% | 9.82% | 32.02% |
Return on Assets
RHHVF
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|<<JR<TXp | LOCK|b? | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|D%lx$LB | LOCK|@T? | $617B | |||
| AbbVie Inc
ABBV
| LOCK|LR&!%?< | LOCK|cG | $464B | |||
| Merck & Co Inc
MRK
| LOCK|#B#tz& | LOCK|#? | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|@yrCT>D | LOCK|!? | $333B | |||
| Novartis AG ADR
NVS
| LOCK|#KlC^#DV | LOCK|^h | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|RVd<c#R# | LOCK|dM< | $243B | |||
| Amgen Inc
AMGN
| LOCK|SD@%JNM | LOCK|Yjb | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|S<^?@B | LOCK|#!F | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Y&&!<b | LOCK|Y& | $165B |
United States